MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

Search

Ultragenyx Pharmaceutical Inc

Cerrado

SectorSanidad

30.91 3.1

Resumen

Variación precio

24h

Actual

Mínimo

29.83

Máximo

30.91

Métricas clave

By Trading Economics

Ingresos

36M

-115M

Ventas

27M

166M

Margen de beneficios

-69.041

Empleados

1,294

EBITDA

35M

-91M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+186.3% upside

Dividendos

By Dow Jones

Próximas Ganancias

4 nov 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

235M

2.9B

Apertura anterior

27.81

Cierre anterior

30.91

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

149 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Ultragenyx Pharmaceutical Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

2 oct 2025, 23:30 UTC

Acciones populares

Stocks to Watch: Rumble, Applied Materials, American Outdoor Brands

2 oct 2025, 21:21 UTC

Ganancias

Applied Materials Expects New Export Rule to Hit 2026 Revenue by $600 Million

3 oct 2025, 00:00 UTC

Adquisiciones, fusiones, absorciones

Warren Buffett's Berkshire Comes to the Aid of Occidental Petroleum -- Again -- WSJ

2 oct 2025, 23:40 UTC

Charlas de Mercado

Gold Edges Higher, Aided by Risks U.S. Shutdown May Weaken Economy -- Market Talk

2 oct 2025, 23:39 UTC

Charlas de Mercado

Japanese Stocks May Edge Higher, Tracking Wall Street Gains -- Market Talk

2 oct 2025, 23:29 UTC

Adquisiciones, fusiones, absorciones

Vistra: Transaction Remains on Track to Close This Qtr or 1Q 2026 >VST

2 oct 2025, 23:29 UTC

Adquisiciones, fusiones, absorciones

Vistra: Received Regulatory Approval From FERC for Acquisition of Certain Subsidiaries Owning Seven Natural-Gas Generation Facilities From Lotus Infrastructure Partners >VST

2 oct 2025, 23:29 UTC

Adquisiciones, fusiones, absorciones

Vistra: Next Step in Acquisition of Gas Generation Fleet With Approval From Federal Energy Regulatory Commission

2 oct 2025, 23:00 UTC

Charlas de Mercado

Warehouse Needs Time to Restore Credibility With Investors -- Market Talk

2 oct 2025, 22:54 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Scales's JV Buyout Lauded by Bull -- Market Talk

2 oct 2025, 22:54 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Global Forex and Fixed Income Roundup: Market Talk

2 oct 2025, 22:46 UTC

Charlas de Mercado

Synlait Milk Loses Bear Following Sale of North Island Assets -- Market Talk

2 oct 2025, 22:46 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

2 oct 2025, 21:17 UTC

Adquisiciones, fusiones, absorciones

Buffett Scores Win in Berkshire's Deal for Occidental Chemicals Unit -- Barrons.com

2 oct 2025, 20:50 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Energy & Utilities Roundup: Market Talk

2 oct 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

2 oct 2025, 20:49 UTC

Adquisiciones, fusiones, absorciones

OpenAI's Latest Funding Deal Returns Focus to AI Economy, Lifting U.S. Stocks -- WSJ

2 oct 2025, 20:00 UTC

Adquisiciones, fusiones, absorciones

Legrand Signs Definitive Agreement To Acquire Avtron Power Solutions, A Global Provider Of Load Banks & Power Quality Solutions >LR.FR

2 oct 2025, 19:20 UTC

Charlas de Mercado

Natural Gas Snaps Winning Streak Despite Small Inventory Rise -- Market Talk

2 oct 2025, 19:10 UTC

Charlas de Mercado

Bank of Canada to Publish Inflation Dashboard in 2026 -- Market Talk

2 oct 2025, 19:04 UTC

Charlas de Mercado

Oil Futures Extend Losses as Markets Brace for Higher Output -- Market Talk

2 oct 2025, 18:46 UTC

Adquisiciones, fusiones, absorciones

Honeywell: Transaction Expected to Improve Annual Free Cash Flow by More Than $100 M Over Next Several Years and Then Decrease Over Time >HON

2 oct 2025, 18:46 UTC

Adquisiciones, fusiones, absorciones

Honeywell: Loss Will Be Excluded From Adjusted EPS >HON

2 oct 2025, 18:46 UTC

Adquisiciones, fusiones, absorciones

Honeywell: Estimated Impact of Divestiture Will Be One-Time Loss of About $115 M >HON

2 oct 2025, 18:45 UTC

Adquisiciones, fusiones, absorciones

Honeywell Will Have No Further Fincl Exposure to the Transferred Liabilities >HON

2 oct 2025, 18:45 UTC

Adquisiciones, fusiones, absorciones

Honeywell Utilized Portion of Cash From Resideo Indemnification and Reimbursement Agreement Termination to Fund Delticus Transaction >HON

2 oct 2025, 18:44 UTC

Adquisiciones, fusiones, absorciones

Honeywell: Delticus Assumed Full Responsibility for Administering and Resolving All Current and Future Asbestos-Related Claims >HON

2 oct 2025, 18:44 UTC

Adquisiciones, fusiones, absorciones

Honeywell and Delticus Contributed About $1.68 B in Cash, as Well as Certain Insurance Assets Related to Legacy Asbestos Liabilities >HON

2 oct 2025, 18:44 UTC

Adquisiciones, fusiones, absorciones

Honeywell: Transaction Strengthens Annual Free Cash Flow Generation >HON

2 oct 2025, 18:43 UTC

Adquisiciones, fusiones, absorciones

Honeywell Divested All Legacy Bendix Asbestos Liabilities, as Well as Certain Non-Bendix Asbestos Liabilities, to Delticus >HON

Comparación entre iguales

Cambio de precio

Ultragenyx Pharmaceutical Inc previsión

Precio Objetivo

By TipRanks

186.3% repunte

Estimación a 12 Meses

Media 85.86 USD  186.3%

Máximo 128 USD

Mínimo 35 USD

De acuerdo con 17 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ultragenyx Pharmaceutical Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

17 ratings

16

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

32.76 / 39.24Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

149 / 371 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.
help-icon Live chat